Rein Therapeutics Announces Initiation of RENEW Phase 2 Trial of LTI-03 in Patients with IPF

The RENEW Phase 2 trial will enroll up to 120 IPF patients with topline data expected in the first half of 2026

In the previously reported Phase 1b study, LTI-03 showed a positive trend in seven out of eight biomarkers evaluated in Cohort 2, with five showing dose dependence and four showing statistically significant improvement in the combined Cohort 1 and 2 data set

Read more at prnewswire.com